Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Go back to Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival| Xenetic Biosciences, Inc. (NASDAQ: XBIO) | Delayed: 2.81 +0.01 (0.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.80 | 52 Week High | $5.20 | |||
| Open | $2.76 | 52 Week Low | $0.21 | |||
| Day High | $2.88 | P/E | N/A | |||
| Day Low | $2.76 | EPS | $-0.01 | |||
| Volume | 7,778 | |||||
